Meeting
2022 ASCO Annual Meeting
The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.
Authors
Shengcheng Lin
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, China
Shengcheng Lin , Kai Ma , Yafei Xu , Xinyi Liu , Xiaochun Huang , Mengli Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3141)
DOI
10.1200/JCO.2022.40.16_suppl.3141
Abstract #
3141
Poster Bd #
133
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
KRAS in non-small cell lung cancer: Single institution experience—What factors are involved?
First Author: Idoroenyi Usua Amanam
Poster
2023 ASCO Annual Meeting
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
First Author: Sukhmani Kaur Padda
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita
Poster
2018 ASCO Annual Meeting
Association of CDKN2A gene alteration with high expression of PD-L1.
First Author: Yan Zhang